QUICKLY.

ED raids premises in crypto-linked PMLA case

Bengaluru: The Enforcement Directorate on Monday raided the premises of the two sons of Karnataka Congress MLA NA Haris, Mohammed Haris Nalapad and Omar Farook Nalapad, and an alleged crypto hacker Srikrishna Ramesh, alias Sriki, in a crypto currency-linked money laundering case, officials said. A dozen premises in the city are being searched under the provisions of the Prevention of Money Laundering Act. The case stems from FIRs and chargesheets filed in a 2017 case of hacking websites. PTI

IIT-M, FedEx try out intracity drone deliveries

Chennai: FedEx, along with the Indian Institute of Technology-Madras, has completed India's first intra-city drone delivery trials in Bengaluru. The trial established that a 53-km road journey, which typically takes over 60 minutes, can be replaced by an aerial route of approximately 39-42 km taking 21 minutes. OUR BUREAU

South Korean tech giant NAVER Corp, TCS ink MoU

New Delhi: South Korean tech giant NAVER Corp and India's largest IT company Tata Consultancy Services (TCS) on Monday inked a memorandum of understanding for mutual cooperation in map services. The MoU was one among 16 agreements signed at the India-Korea Business Forum, aimed at strengthening bilateral cooperation. PTI

Haryana drugs regulator seizes fake Mounjaro in Gurugram, says Eli Lilly

PROTECTING PATIENTS. Pharma major said it is supporting probe into seizure, reported to be worth ₹70 lakh

Our Bureau
Mumbai

American healthcare company Eli Lilly said it has been alerted on the seizure of "suspicious and counterfeit products" that allegedly carry its product brand name Mounjaro (Tirzepatide).

Mounjaro is prescribed to treat obesity and has been in the headlines, as the scramble for GLP-1 drugs for weight-loss and diabetes get fuelled beyond the doctor's chambers, through peer-pressure and online hard-sell, among others.

"The said seizure resulted from an enforcement drive conducted in Gurugram by officials from the state drugs regulatory authority, Haryana," an Eli Lilly and Company (India) spokesperson told *businessline*.

The company was responding to reports that ₹70 lakh worth of fake Mounjaro had been seized in Gurugram. This comes on the heels of an international investigation into the alleged supply of tampered/counterfeit cancer medicine and diversion of supply chains in countries, including India.

SUPPORTS PROBE

Lilly, meanwhile, said it welcomed the regulatory authority's action against "illicit medicines." Further, it added, "We are actively supporting the investigation and will continue to work with regulatory and law enforcement authorities worldwide to protect patients from the risks of counterfeit products. Stronger, coordinated enforcement must be sustained if we are to protect patients from unsafe fake medicines."

MARKET DEMAND. A Mounjaro injection used for weight loss procedures at a clinic (file photo) REUTERS

Mounjaro has been pegging over ₹100 crore sales in India over the last several months, and has been leading the estimated ₹1,600 crore GLP-1 drugs (for obesity and diabetes) segment — despite being the highest priced drug in the segment.

This category of weight-loss and diabetes drugs have been seeing an increase in demand, after a patent on semaglutide from Danish healthcare company Novo Nordisk went off patent, late March. The loss of patent has resulted in over 26 domestic brands being launched in over 10 days — and at prices between 50 to 80 per cent of the innovator price. And this has further fuelled the demand for these products.

NSQ DRUGS

Meanwhile, in a separate listing of Not of Standard Quality (NSQ) and spurious drugs, for March-2026, the Indian drug regulator said, that the Central Drugs Laboratories had identified 48 drug samples to be NSQ, while State Drugs Testing Laboratories identified 120 drugs samples.

APTEL pulls up DERC, speed up liquidation of regulatory assets, it says

Rishi Ranjan Kala
New Delhi

The Appellate Tribunal for Electricity (APTEL) on Monday directed the Delhi Electricity Regulatory Commission (DERC) to immediately commence the liquidation of regulatory assets within three weeks.

Besides, the tribunal rejected DERC's plea for extension of time by three months, till July 2026, for liquidating regulatory assets (RAs) worth ₹38,552 crore of Delhi discoms as per the Supreme Court judgment (August 6, 2025).

In August 2025, the Supreme Court directed that the RAs including carrying costs have to be paid within three years to Delhi's private discoms. RAs are deferred revenue gaps that have to be recovered via tariffs.

END-CONSUMER HIT

"We direct the Commission to commence the process of liquidation of RAs as per the RA judgement of the Supreme Court within three weeks from today (April 20) positively. However, considering the statutory procedure to be followed for issue of the true up order, time up to June 30, 2026 is granted for passing true up order of FY24," the APTEL said.

The tribunal said that it finds it evident that the DERC has been delaying the liquidation of regulatory assets for one reason or the other thereby permitting an increase in the amount of regulatory assets day by day which would place additional burden upon the end consumers of the electricity in NCT of Delhi.

"We do not see any cogent and plausible reason which is preventing the Commission (DERC) to commence the liquidation of regulatory assets. The entire conduct of the Commission in this regard appears to be *mala fide* and needs to be deprecated," it added.

"The Commission has been holding back its hands on the regulatory assets despite giving repeated undertakings and assurances in this regard to the Supreme Court, to the Delhi High Court and to this Tribunal the details of which have been noted herein above, as pointed by the learned counsel for Delhi discoms," the order emphasised.

The APTEL set aside the Delhi Electricity Regulatory Commission's (DERC) move to conduct an audit of Delhi's power distribution companies (Discoms) through the Comptroller and Auditor General (CAG).

Paediatrics academy chief reaffirms ORS recommendation

PT Jyothi Datta
Mumbai

As discussions on oral rehydration salts (ORS) and corporate funding of medical events continue to dominate conversations in the doctor community, the Indian Academy of Paediatrics chief has sought to reiterate its position on ORS, besides clarifying on "academic grants" from companies.

ORS is a drug, while electrolyte drinks are food products that can never be used as a substitute for ORS, said IAP National President Neelam Mohan.

As paediatricians, IAP's stand is to be with science and "we do not have to talk about electrolyte drinks and confuse the public," Dr Mohan told *businessline*.

IAP is appreciative of the Centre's directive allowing only products adhering to the World Health Organisation's ORS formula to carry 'ORS' branding on their packs, she said. Pointing out that IAP only recommends WHO-ORS for clinical use and does not promote electrolyte drinks or health beverages, she said branding of food products was outside its purview.

Dr Mohan is also Senior Director (pediatric gastroenterology and hepatology), Medanta Medicity (Gurugram).

ACADEMIC GRANTS

Addressing the contentious issue of corporate funding, Mohan said "academic grants", when taken from companies, are in compliance with the IMS Act, UCPMP and NMC guidelines and do not influence the IAP's scientific content or recommendations.

(The IMS Act is the Infant Milk Substitutes, Feeding Bottles and Infant Foods (Regulation of Production, Supply and Distribution) Act; UCPMP is the Uniform Code for Pharmaceutical Marketing Practices; and the NMC Act is the National Medical Commission Act.) The IAP President was responding to concerns being discussed among members of the paediatric community, following the resignation of Dr Sivaranjani Santosh from the IAP about a week ago.

Dr Santosh had flagged the issues of corporate funding besides calling for clear differentiation between ORS products (mandated to abide by the WHO formula), and electrolyte drinks that are food products.

Looking to counter further criticism, Dr Mohan said that the IAP represents over 50,000 doctors who reiterate that children's health is a priority, and has always warned against non-standard formulations.

Building a ₹600-crore activewear business, the Technosport way

T E Raja Simhan
Tiruppur

Leaving a stable job at Microsoft in 2007, at a time when the IT sector was booming, Sunil Jhunjhunwala took a leap of faith into entrepreneurship.

Armed with just ₹20 lakh in family savings, he entered the textile industry to launch Technosport in Tiruppur, a decision that has since transformed into a ₹600 crore activewear business, now eyeing ₹1,000 crore in revenue this fiscal.

In its early years, Technosport was not a manufacturer but a trader. The company sourced synthetic fabrics from hubs such as Ludhiana and Silvassa, got garments stitched in Tiruppur and sold them under its own label.

The founding insight was straightforward: While global brands such as Nike, Adidas and Reebok were gaining popularity in India, their products remained unaffordable for most consumers. Technosport sought to bridge that gap by "democratising" performance wear — offering comfort, durability and functionality at accessible price points.

EARLY YEARS

However, the journey was far from smooth.

In the beginning, while the company could replicate the look of global products, it struggled to match their performance.

The turning point came in 2010, when Jhunjhunwala visited textile expos in China and Taiwan. There, he gained insights into the science behind high-performance fabrics, particularly moisture management and durability — key differentiators for global brands.

The company moved from merely sourcing fabrics to understanding and engineering them. Over time, it invested in building in-house capabilities, focusing on synthetic fibres suited to India's climate and lifestyle, Sunil Jhunhunwala, Co-founder at TechnoSport, told *businessline* at his factory inside the Perundurai Sipcot Industrial Estate, near Tiruppur.

The brand also repositioned itself from "sportswear" to "activewear" — a broader category catering not just to athletes but everyday users, including office-goers, delivery personnel and farmers. This shift significantly expanded its market in a price-sensitive country such as India.

Today, Technosport operates a vertically integrated fabric manufacturing facility in and around Tiruppur with a capacity of about 30 tonnes per day, translating into over 1.2 lakh garments.

While garmenting continues to be outsourced, control over fabric production — its key differentiator — has enabled the company to maintain both quality and cost efficiency.

Sustainability has emerged as another pillar of growth. The company's plant runs on renewable energy, adheres to zero liquid discharge norms and focuses on reducing its carbon footprint.

Follow NDSA guidelines as you undertake Medigadda restoration work: Telangana CM

Our Bureau
Hyderabad

The Congress government in Telangana has decided to undertake the corrective measures at Medigadda, Annaram, and Sundilla barrages, which are the key components of the Kaleshwaram Irrigation Project.

The project turned into a major political controversy during the 2023 Assembly elections, with the then BRS government drawing flak for the collapse of a few pillars at the Medigadda barrage, resulting in significant water loss and raising questions about the project's future.

While the Opposition BRS argued that the barrage can easily be revived, the Revanth Reddy government alleged that the KCR government wasted thousands of crores of public money.

REVIVAL DISCUSSED

However, two years after coming to power, the State government, has decided to revive the project. Chief Minister A Revanth Reddy, along with Irrigation Minister Uttam Kumar Reddy and top officials, visited the barrage on Monday evening and held a review meeting to discuss possible measures to revive the project.

He directed the officials to undertake the works in accordance with the NDSA (National Dam Safety Authority) guidelines. "After studying the issue, we now have clarity on how to go about it to rectify the defects at Medigadda, Annaram, and Sundilla," he said.

"You must secure NDSA approvals for every task that you undertake," he said.

Alleging that the BRS government had disregarded the NDSA report that flagged the challenges with regard to the project, he reminded that the State Government had recommended for a Central Bureau of Investigation (CBI) investigation into the alleged irregularities.